Abstract
The pregnane X receptor (PXR) has three known major transcript variants resulting from alternative splicing. The less well characterized variants T2 and T3 are identical to the well described variant T1 except for a 39-amino acid N-terminal extension in T2 and an internal 37-amino acid deletion in T3. We have developed reverse transcription-polymerase chain reaction (RT-PCR) methods to detect and quantify each human PXR (hPXR) in human liver and intestinal tissues and HepG2 and Caco-2 cell lines. All three isoforms were expressed in hepatic cells, whereas only T1 transcripts were found in Caco-2 cells. In general, most normal human liver and intestinal mucosa contained all three hPXR variants, but considerable interindividual variation in expression levels was found. The effect of each hPXR variant on expression of UDP-glucuronosyltransferase (UGT) UGT1A and UGT2B family isoforms was investigated in transiently transfected HepG2 and Caco-2 cells. As a family, UGT1A transcripts were up-regulated by T1 and T2 but not T3. Isoform-specific RT-PCR revealed that UGT1A1, 1A3, and 1A4 were the major isoforms induced in both cell lines. The levels of several UGT1A isoforms were also examined in human liver samples from a number of donors with characterized PXR expression. The data suggest that individual variation in PXR expression may account for differential expression of some UGT isoforms between subjects.
Footnotes
-
↵2 Abbreviations used are: PXR, pregname X receptor; RIF, rifamppicin; hPXR, human PXR; NR, nuclear receptor; UGT, UDP-glucuronsytransferase; DMEM, Dulbecco's modified Eagle's medium; RT-PCR, reverse transcription-polymerase chain reaction; dNTP, deoxynucleoside-5′-triphosphate; UTR, untranslated region; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; P450, cytochrome P450.
-
This work was supported in part by National Institutes of Health Grants DK45123, DK60109 (A.R.-P.), 20 RR016460 (T.L.), and tobacco settlement funds (A.R.-P.). P.M. is a National Health and Medical Research Council Senior Principal Research Fellow and is supported by grants from the Cancer Council South Australia and the National Health and Medical Research Council of Australia. W.X. is supported by NIH Grant ES12479 and Department of Defense Grant BC23189. T.L. is also supported by funds from the Biomedical Research Infrastructure Network.
-
J.-M.H. and D.G.-S. contributed equally to this work.
-
↵1 Present address: Unité de Biochimie-Pharmacologie-Toxicologie, Université de Bourgogne, Dijon, France.
- Received August 27, 2003.
- Accepted November 11, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|